Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV cohort study

Journal of Acquired Immune Deficiency Syndromes

Volumn 31, Issue 1, 2002, Pages 50-55

  Bernasconi, Enos ^a   Boubaker, Karim ^a   Junghans, Cornelia ^a   Flepp, Markus ^a   Furrer, Hans Jakob ^a   Haensel, Alexander ^a   Hirschel, Bernard ^a   Boggian, Katia ^a   Chave, Jean Philippe ^a   Opravil, Milos ^a   Weber, Rainer ^a   Rickenbach, Martin ^a   Telenti, Amalio ^a  

^a Ospedale Civico Lugano   (Switzerland)

Author keywords

Adverse effects; Antiretroviral drugs; HIV; Lipodystrophy

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; LACTIC ACID; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; BODY DISTRIBUTION; BODY FAT; CLINICAL TRIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR;

EID: 0036737110     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200209010-00007     Document Type: Article

References (10)

1. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-8.
2. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving longterm nucleoside analogue therapy. AIDS 1999;13:1659-67.
3. Brinkman K, Smeitink JA, Romijn JA, et al. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999;354:1112-5.
4. Moyle G. Mitochondrial toxicity hypothesis for lipoatrophy: a refutation. AIDS 2001;15:413-5.
5. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999;353:863-8.
6. Fellay J, Boubaker K, Ledergerber B, et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 2001;358:1322-7.
7. Carr A, Miller J, Law M, et al. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000;14:F25-32.
8. Lichtenstein KA, Ward DJ, Moorman AC, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001;15:1389-98.
9. Heath KV, Hogg RS, Chan KJ, et al. Lipodystrophy-associated morphologic, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS 2001;15:231-9.
10. Mallal S, Nolan D. Light and electron microscopy findings in subcutaneous fat in antiretroviral treated and naive HIV-infected patients [abstract LbPeB7054]. 13th International AIDS Conference, Durban, July 9-14, 2000.